• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肉毒杆菌毒素与多发性硬化症

Botulinum toxin in multiple sclerosis.

作者信息

Jost Wolfgang H

机构信息

Dept. of Neurology, Deutsche Klinik für Diagnostik, Aukammallee 33, 65191, Wiesbaden, Germany.

出版信息

J Neurol. 2006 Feb;253 Suppl 1:I16-20. doi: 10.1007/s00415-006-1104-0.

DOI:10.1007/s00415-006-1104-0
PMID:16477480
Abstract

Local administration of botulinum toxin (BoTx) inhibits presynaptic acetylcholine release. All cholinergically innervated muscles and glands can be paralyzed accordingly. Studies on the application of BoTx in multiple sclerosis have shown good results for focal spasticity, in particular, of the extremities. The first promising data were published on bladder disorders, especially with regard to detrusor sphincter dyssynergia and detrusor hyperreflexia. Hyperhidrosis, hypersalivation and proctologic symptoms might be other areas of application. Approval, however, has been greatly restricted which limits the therapeutic range of use.

摘要

局部注射肉毒杆菌毒素(BoTx)可抑制突触前乙酰胆碱释放。相应地,所有受胆碱能神经支配的肌肉和腺体都会麻痹。关于BoTx在多发性硬化症中的应用研究表明,其对局部痉挛,尤其是肢体痉挛有良好效果。关于膀胱功能障碍,尤其是逼尿肌括约肌协同失调和逼尿肌反射亢进的首批有前景的数据已发表。多汗症、唾液分泌过多和直肠症状可能是其他应用领域。然而,其获批情况受到极大限制,这限制了其治疗应用范围。

相似文献

1
Botulinum toxin in multiple sclerosis.肉毒杆菌毒素与多发性硬化症
J Neurol. 2006 Feb;253 Suppl 1:I16-20. doi: 10.1007/s00415-006-1104-0.
2
The place of the botulinum toxin in the management of multiple sclerosis.肉毒杆菌毒素在多发性硬化症治疗中的作用
Clin Neurol Neurosurg. 2010 Sep;112(7):592-6. doi: 10.1016/j.clineuro.2010.04.010. Epub 2010 Jul 8.
3
Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients.肉毒杆菌A毒素对多发性硬化症患者逼尿肌括约肌协同失调影响的安慰剂对照、随机、双盲研究。
J Neurol Neurosurg Psychiatry. 2005 Dec;76(12):1670-6. doi: 10.1136/jnnp.2004.045765.
4
Stroke, spasticity, and botulinum toxin.中风、痉挛与肉毒杆菌毒素
N Engl J Med. 2002 Aug 8;347(6):382-3. doi: 10.1056/NEJMp020071.
5
[Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis].[肉毒杆菌毒素治疗多发性硬化症患者的髋内收肌痉挛]
Wien Klin Wochenschr. 2001;113 Suppl 4:20-4.
6
[Pharmacological treatment of spasticity in multiple sclerosis].[多发性硬化症痉挛的药物治疗]
Rev Neurol (Paris). 2012 Apr;168 Suppl 3:S62-8. doi: 10.1016/S0035-3787(12)70049-8.
7
[Botulinum toxin in spasticity treatment].[肉毒杆菌毒素在痉挛治疗中的应用]
Neurol Neurochir Pol. 1998;32 Suppl 1:71-84.
8
[Treatment with botulinum toxin in neurologic pediatrics].[肉毒杆菌毒素在神经儿科的治疗]
Kinderkrankenschwester. 2007 Jul;26(7):274-6.
9
Botulinum A toxin treatment for detrusor-sphincter dyssynergia in spinal cord disease.
Spinal Cord. 1998 Feb;36(2):91-4. doi: 10.1038/sj.sc.3100517.
10
Botulinum toxin and spasticity.肉毒杆菌毒素与痉挛
J Neurol Neurosurg Psychiatry. 2000 Aug;69(2):143-7. doi: 10.1136/jnnp.69.2.143.

引用本文的文献

1
Botulinum Toxin Therapy: A Comprehensive Review on Clinical and Pharmacological Insights.肉毒杆菌毒素疗法:临床与药理学见解的全面综述
J Clin Med. 2025 Mar 16;14(6):2021. doi: 10.3390/jcm14062021.
2
Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force.肉毒杆菌毒素治疗多发性硬化症中的痉挛:IAB-运动障碍跨学科工作组特别工作组的综述与建议
J Neurol. 2017 Jan;264(1):112-120. doi: 10.1007/s00415-016-8304-z. Epub 2016 Oct 27.
3
Efficacy of botulinum toxin type a for treating chronic low back pain.

本文引用的文献

1
Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study.A型肉毒杆菌毒素是治疗神经源性尿失禁的一种安全有效的方法:一项单次治疗、随机、安慰剂对照的6个月研究结果。
J Urol. 2005 Jul;174(1):196-200. doi: 10.1097/01.ju.0000162035.73977.1c.
2
Botulinum toxin type A therapy for chronic tension-type headache: fact versus fiction.
Pain. 2005 Jul;116(1-2):166-7; author reply 167. doi: 10.1016/j.pain.2005.03.033.
3
[Therapy of pain syndromes in multiple sclerosis -- an overview with evidence-based recommendations].[多发性硬化症疼痛综合征的治疗——基于证据的建议概述]
A型肉毒杆菌毒素治疗慢性下腰痛的疗效
Anesth Pain Med. 2011 Fall;1(2):77-80. doi: 10.5812/kowsar.22287523.1845. Epub 2011 Sep 26.
4
Gait abnormalities in multiple sclerosis: pathogenesis, evaluation, and advances in treatment.多发性硬化症的步态异常:发病机制、评估和治疗进展。
Curr Neurol Neurosci Rep. 2011 Oct;11(5):507-15. doi: 10.1007/s11910-011-0214-y.
Fortschr Neurol Psychiatr. 2005 May;73(5):268-85. doi: 10.1055/s-2004-830193.
4
Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence.重度神经源性逼尿肌过度活动和尿失禁患者重复注射肉毒杆菌毒素A治疗逼尿肌的疗效
Eur Urol. 2005 May;47(5):653-9. doi: 10.1016/j.eururo.2004.11.009. Epub 2005 Jan 15.
5
Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra.110例患者膀胱或尿道注射A型肉毒杆菌毒素的单机构经验。
Urology. 2005 Jan;65(1):37-41. doi: 10.1016/j.urology.2004.08.016.
6
[Treatment of the spastic drop foot with botulinum toxin type A in adult patients].[肉毒杆菌毒素A治疗成年患者痉挛性足下垂]
Wien Klin Wochenschr. 2001;113 Suppl 4:25-9.
7
Safety of botulinum toxin type A: a systematic review and meta-analysis.A型肉毒杆菌毒素的安全性:一项系统评价和荟萃分析。
Curr Med Res Opin. 2004 Jul;20(7):981-90. doi: 10.1185/030079904125003962.
8
Treatment of chronic tension-type headache with botulinum toxin: a double-blind, placebo-controlled clinical trial.肉毒杆菌毒素治疗慢性紧张型头痛:一项双盲、安慰剂对照临床试验。
Cephalalgia. 2004 Aug;24(8):675-80. doi: 10.1111/j.1468-2982.2004.00738.x.
9
European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity.欧洲对200例因神经源性逼尿肌过度活动导致尿失禁而接受肉毒杆菌A毒素注射到逼尿肌治疗的经验。
Eur Urol. 2004 Apr;45(4):510-5. doi: 10.1016/j.eururo.2003.12.004.
10
Botulinum toxin in neuro-urological disorders.
Mov Disord. 2004 Mar;19 Suppl 8:S142-5. doi: 10.1002/mds.20068.